Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT03835819 |
| Title | A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) |
| Recruitment | Recruiting |
| Gender | female |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Dana-Farber Cancer Institute |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Dana Farber Cancer Institute | RECRUITING | Boston | Massachusetts | 02215 | United States | Details |
| University of Massachusetts | RECRUITING | Worcester | Massachusetts | 01605 | United States | Details |
| Northwell Cancer Institute | RECRUITING | Lake Success | New York | 11042 | United States | Details |